After six years at Bristol-Myers Squibb as a medical-marketing Manager, Dr Richard joined Aventis Pharma as European Clinical Project Manager in a French-Japanese joint-venture, then as Director in the global anti-infectives corporate clinical department. In 2000, she joined GlaxoSmithKline in the UK as Sr Director with responsibility for a portfolio of anti-infectives. Thereafter Dr Richard was appointed VP Clinical Development in Sanofi Pasteur France . From 2008, she was a Medical Advisor for several biotech companies in Switzerland and France, and for a Capital Venture Fonds.
Dr. Richard is an M.D., she received her diploma in clinical immunology, pharmacology/ pharmacokinetics, and an MBA from CEDEP-INSEAD.
"We are very pleased to see Dr. Richard join the team at AiCuris as CMO. She has a profound background in infectious diseases and a great development and management expertise", comments AiCuris CEO, Prof. Helga Rübsamen-Schaeff. "I am extremely happy to join the experienced and highly qualified Development team at AiCuris. The R&D portfolio is very promising and I am thrilled with this opportunity to develop this portfolio further at AiCuris and to bring my competences to the Management Team", adds Dr. Marie-Paule Richard.
About AiCuris - www.aicuris.com
AiCuris GmbH & Co KG (the name is derived from: anti infective cures) is a privately held company located in Wuppertal, Germany . AiCuris is devoted to research and clinical development of novel, resistance-breaking drugs for the treatment of viruses like Cytomegalovirus (HCMV), Herpes Simplex, Hepatitis B, HIV and Hepatitis C as well as for resistant Gram positive and Gram negative bacterial infections in hospitals. Furthermore, the portfolio comprises two immune modulators. Link to the high resolution picture: http://www.aicuris.com/images/dsc_0168.jpg
Contact:
AiCuris GmbH & Co. KG Sandra Wildhagen Friedrich-Ebert-Str. 475/Building 302 42117 Wuppertal Phone +49 202 317 63 1176 Fax +49 202 317 63 1177 E-mail press@aicuris.com Internet www.aicuris.com
